Uğur Şahin, BioNTech CEO (Sebastian Gollnow/picture-alliance/dpa/AP Images)

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

As BioN­Tech con­tin­ues to beef up its on­col­o­gy pipeline, it’s once again turn­ing to a Chi­nese part­ner.

The Ger­man biotech is putting down $55 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.